# Pitavastatin

Drug · id `cardio:pitavastatin` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Livalo

Browse, condition area: Risk and prevention; Coronary and vascular disease  

## In plain language

Pitavastatin is a statin, a medicine taken by mouth to lower LDL cholesterol. The FDA label says it is indicated to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia. Livalo is the brand name on the label read.

## Technical summary

RxNorm ingredient 861634; UNII IYD54XEG3W. The label names the substance as pitavastatin calcium, so UNII IYD54XEG3W is the UNII of the salt form and is a broad match. MeSH lists this substance under entry terms and not as its own descriptor, so no MeSH identifier is recorded. Class: HMG-CoA Reductase Inhibitor (FDA established pharmacologic class, RxClass). The label read is the Kowa Pharmaceuticals America, Inc. label for LIVALO (pitavastatin calcium), application NDA022363, effective 2026-03-31 in openFDA. This page records the label indication and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: People for whom the US label of pitavastatin lists an indication: adults with primary hyperlipidemia

Recipient: Adult; Population: Patients described in the indications section of the label, the passage read here being the adult LDL-cholesterol indication.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the passage read states; Follow-up: Not applicable (label statement)

### The US label of LIVALO (pitavastatin calcium), in the Kowa Pharmaceuticals America, Inc. version dated 2026-03-31 in openFDA, lists the medicine to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Patients described in the indications section of the label, the passage read here being the adult LDL-cholesterol indication.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the passage read states; Follow-up: Not applicable (label statement)
- Limitations: This claim records one thing the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label lists other indications that were not recorded; contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-07
- Sources:
  1. Supports: openFDA drug label record for LIVALO (pitavastatin calcium), Kowa Pharmaceuticals America, Inc. label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 44dcbf97-99ec-427c-ba50-207e0069d6d2 (manufacturer Kowa Pharmaceuticals America, Inc., application NDA022363), returned on 2026-11-07. The label text is dated 2026-03-31 (effective\_time). Other openFDA records of pitavastatin labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2244dcbf97-99ec-427c-ba50-207e0069d6d2%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-08T02:09:29Z. Source state: Current. Version fingerprint: 57ec858494fdaae2ff3f5e8c1545ff2fc4750120c8b1dca254bd489647b97ee9.
     How it applies: The label sentence that gives the LDL-cholesterol indication.
  2. Background: openFDA drug label record for LIVALO (pitavastatin calcium), Kowa Pharmaceuticals America, Inc. label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 44dcbf97-99ec-427c-ba50-207e0069d6d2 (manufacturer Kowa Pharmaceuticals America, Inc., application NDA022363), returned on 2026-11-07. The label text is dated 2026-03-31 (effective\_time). Other openFDA records of pitavastatin labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2244dcbf97-99ec-427c-ba50-207e0069d6d2%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-08T02:09:29Z. Source state: Current. Version fingerprint: 57ec858494fdaae2ff3f5e8c1545ff2fc4750120c8b1dca254bd489647b97ee9.
     How it applies: Effective date of the label text read, 20260331.

## Connected pages

- Pitavastatin is an HMG-CoA reductase inhibitor (FDA established pharmacologic class in RxClass): Statins (`cardio:statins`)
- FDA label lists lowering LDL cholesterol as an indication: Dyslipidemia (`cardio:dyslipidemia`) [a claim, not a settled fact; see claim `cardio:claim-fda-pitavastatin-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 8 registry trials

## Provenance

Content hash: 0897bc53b0f65411a4f021549d892d6abd83796be4c2b65767d410c691a10bb6
Last substantive edit: 2026-11-07
Evidence last checked: 2026-11-07
